Search research articles
Contact Us
Filters
Showing results (31-40 of 172) with videos related to
Page
of 18
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
September 4, 2015
Impact of Concurrent PIK3CA Mutations on Response to EGFR Tyrosine Kinase Inhibition in EGFR-Mutant Lung Cancers and on Prognosis in Oncogene-Driven Lung Adenocarcinomas
Juliana Eng, Kaitlin M Woo, Camelia S Sima, et al.
Lung Cancer (Amsterdam, Netherlands)
|
September 18, 2021
Intra- and inter-reader agreement of iRECIST and RECIST 1.1 criteria for the assessment of tumor response in patients receiving checkpoint inhibitor immunotherapy for lung cancer
Sandra Huicochea Castellanos, Andrew Pagano, Andrew J Plodkowski, et al.
International Journal of Cancer
|
March 7, 2020
Phase 1 study of epacadostat in combination with atezolizumab for patients with previously treated advanced nonsmall cell lung cancer
Matthew D Hellmann, Scott Gettinger, Laura Q M Chow, et al.
The Lancet. Oncology
|
January 4, 2014
Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint
Matthew D Hellmann, Jamie E Chaft, William N William, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 11, 2018
Safety of Programmed Death-1 Pathway Inhibitors Among Patients With Non-Small-Cell Lung Cancer and Preexisting Autoimmune Disorders
Giulia C Leonardi, Justin F Gainor, Mehmet Altan, et al.
Leukemia & Lymphoma
|
June 6, 2013
Treatment of primary mediastinal B-cell lymphoma with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone is associated with a high rate of primary refractory disease
Jacob D Soumerai, Matthew D Hellmann, Yang Feng, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
January 16, 2023
Baseline Radiomic Signature to Estimate Overall Survival in Patients With NSCLC
Laurent Dercle, Matthew Fronheiser, Naiyer A Rizvi, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
December 2, 2014
Clinical characteristics and course of 63 patients with BRAF mutant lung cancers
Anya M Litvak, Paul K Paik, Kaitlin M Woo, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
May 16, 2021
The Impact of Durvalumab on Local-Regional Control in Stage III NSCLCs Treated With Chemoradiation and on KEAP1-NFE2L2-Mutant Tumors
Narek Shaverdian, Michael Offin, Annemarie F Shepherd, et al.
Cancer Cell
|
June 21, 2024
Intratumoral immune triads are required for immunotherapy-mediated elimination of solid tumors
Gabriel Espinosa-Carrasco, Edison Chiu, Aurora Scrivo, et al.
Page
of 18
Search research articles
Search
Showing results (31-40 of 172) with videos related to
Sort By:
Page
of 18
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
September 4, 2015
Impact of Concurrent PIK3CA Mutations on Response to EGFR Tyrosine Kinase Inhibition in EGFR-Mutant Lung Cancers and on Prognosis in Oncogene-Driven Lung Adenocarcinomas
Juliana Eng, Kaitlin M Woo, Camelia S Sima, et al.
Lung Cancer (Amsterdam, Netherlands)
|
September 18, 2021
Intra- and inter-reader agreement of iRECIST and RECIST 1.1 criteria for the assessment of tumor response in patients receiving checkpoint inhibitor immunotherapy for lung cancer
Sandra Huicochea Castellanos, Andrew Pagano, Andrew J Plodkowski, et al.
International Journal of Cancer
|
March 7, 2020
Phase 1 study of epacadostat in combination with atezolizumab for patients with previously treated advanced nonsmall cell lung cancer
Matthew D Hellmann, Scott Gettinger, Laura Q M Chow, et al.
The Lancet. Oncology
|
January 4, 2014
Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint
Matthew D Hellmann, Jamie E Chaft, William N William, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 11, 2018
Safety of Programmed Death-1 Pathway Inhibitors Among Patients With Non-Small-Cell Lung Cancer and Preexisting Autoimmune Disorders
Giulia C Leonardi, Justin F Gainor, Mehmet Altan, et al.
Leukemia & Lymphoma
|
June 6, 2013
Treatment of primary mediastinal B-cell lymphoma with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone is associated with a high rate of primary refractory disease
Jacob D Soumerai, Matthew D Hellmann, Yang Feng, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
January 16, 2023
Baseline Radiomic Signature to Estimate Overall Survival in Patients With NSCLC
Laurent Dercle, Matthew Fronheiser, Naiyer A Rizvi, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
December 2, 2014
Clinical characteristics and course of 63 patients with BRAF mutant lung cancers
Anya M Litvak, Paul K Paik, Kaitlin M Woo, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
May 16, 2021
The Impact of Durvalumab on Local-Regional Control in Stage III NSCLCs Treated With Chemoradiation and on KEAP1-NFE2L2-Mutant Tumors
Narek Shaverdian, Michael Offin, Annemarie F Shepherd, et al.
Cancer Cell
|
June 21, 2024
Intratumoral immune triads are required for immunotherapy-mediated elimination of solid tumors
Gabriel Espinosa-Carrasco, Edison Chiu, Aurora Scrivo, et al.
Page
of 18